Miyazaki et al. suggested that AIM is involved in the progression of metabolic syndrome, including obesity and IR, in both an advancing and inhibitory fashion[9], but the impact of AIM on the pathogenesis of HCV-related chronic liver disease has not been investigated. Here, CD5L is linked to metabolic syndrome.